Oxygenation status of gynecologic tumors: What is the optimal hemoglobin level?

Strahlentherapie und Onkologie

Volumn 178, Issue 12, 2002, Pages 727-731

  Vaupel, Peter ^a   Thews, Oliver ^a   Mayer, Arnulf ^a   Höckel, Susanne ^b   Höckel, Michael ^b  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Anemia; Cervical cancer; Hb concentration; Oxygen transport capacity; Tumor oxygenation; Viscous resistance to flow; Vulvar cancer

Indexed keywords

HEMOGLOBIN;

ANEMIA; ARTICLE; BLOOD FLOW; BLOOD VISCOSITY; CANCER RECURRENCE; DATA ANALYSIS; ELECTRODE; FEMALE; FEMALE GENITAL TRACT TUMOR; HEMOGLOBIN DETERMINATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOXIA; MAJOR CLINICAL STUDY; OXYGEN TENSION; OXYGEN TRANSPORT; PATHOGENESIS; TISSUE OXYGENATION; UTERINE CERVIX CARCINOMA; VULVA CANCER;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CELL HYPOXIA; CERVIX UTERI; FEMALE; HEMOGLOBINOMETRY; HUMANS; MIDDLE AGED; NEOPLASM STAGING; OXYGEN CONSUMPTION; PROGNOSIS; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS; VULVA; VULVAR NEOPLASMS;

EID: 0036904009     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00066-002-1081-x     Document Type: Article

References (20)

1. Becker A, Stadler P, Lavey RS, Hänsgen G, Kuhnt T, Lautenschläger C, Feldmann HJ, Molls M, Dunst J. Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-66.
2. Fyles AW, Milosevic M, Pintilie M, Syed A, Hill RP. Anemia, hypoxia and transfusion in patients with cervix cancer: A review. Radiother Oncol 2000; 57:13-9.
3. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
4. Höckel M, Schlenger K, Höckel S, Vaupel P. Association between tumor hypoxia and malignant progression: The clinical evidence in cancer of the uterine cervix. In: Vaupel P, Kelleher DK, eds. Tumor Hypoxia. Stuttgart: Wissenschaftliche Verlagsgesellschaft, 1999:65-74.
5. 2 tension measurements. Cancer Res 1991;51:6098-102.
6. Höckel M, Vaupel P. Tumor hypoxia: Definitions and current clinical, biologic and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
7. Höckel M, Vaupel P. Prognostic significance of tissue hypoxia in cervical cancer. CME J Gynecol Oncol 2001;6:216-25.
8. 2 availability during hemodilution. Adv Exp Med Biol 1984;180:281-91.
9. 2-measurements as predictive assay in the treatment of carcinoma of the uterine cervix. Radiother Oncol 1999;53:99-104.
10. Mertzlufft F. Normal values for hemoglobin concentration. In: Zander R, Mertzlufft F, eds. The Oxygen Status of Arterial Blood. Basel-New York: Karger, 1991:162-6.
11. Milosevic M, Quirt I, Levin W, Fyles A, Manchul L, Chapman W. Intratumoral sickling in a patient with cervix cancer and sickle trait: Effect on blood flow and oxygenation. Gynecol Oncol 2001;83:428-31.
12. Sevick EM, Jain RK. Viscous resistance to blood flow in solid tumors: Effect of hematocrit on intratumor blood viscosity. Cancer Res 1989;49:3513-9.
13. Sevick EM, Jain RK. Viscous resistance to blood flow in the tumor microcirculation: Clinical implications. Funktionsanalyse Biolog Systeme 1991; 20:53-63.
14. Thews O, Vaupel P. Relevant parameters for describing the oxygenation status of solid tumors. Strahlenther Onkol 1996;172:239-43.
15. Thomas L. Hämoglobine. In: Thomas L, Hrsg. Labor und Diagnose, 5. Aufl. Frankfurt: TH Books Verlagsgesellschaft, 1998:487-91.
16. Vaupel PW. Blood Flow, Oxygenation, Tissue pH Distribution and Bioenergetic Status of Tumors. Berlin: Ernst Schering Research Foundation, Lecture 23, 1994.
17. Vaupel P, Höckel M. Hypoxie beim zervixkarzinom: Pathogenese, charakterisierung und biologische/klinische konsequenzen. Zentralbl Gynäkol 2001;123:192-7.
18. Vaupel P, Thews O, Höckel M. Treatment resistance of solid tumors: Role of hypoxia and anemia. Med Oncol 2001;18:243-59.
19. Vaupel P, Thews O, Kelleher DK, Höckel M. Oxygenation of human tumors. The Mainz experience. Strahlenther Onkol 1998;174:Suppl IV:6-12.
20. Zander R. Optimaler hämatokrit 30%: Abschied von einer illusion. Infusionsther Transfusionsmed 1999;26:186-90.